Guidance and quality standards Awaiting development

Skip to filters Skip to results

Showing 101 to 125 of 340

Type: GuidanceRemove Type: Guidance filter
Type: Quality standardRemove Type: Quality standard filter

Guidance and quality standards awaiting development
Title	Type
Electrically stimulated intravesical therapy for Interstitial Cystitis	Interventional procedures guidance
Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847	Technology appraisal guidance
Elinzanetant for treating vasomotor symptoms associated with menopause TS ID 11917	Technology appraisal guidance
Encorafenib with binimetinib for treating BRAF V600E mutation-positive metastatic non-small-cell lung cancer [ID6177]	Technology appraisal guidance
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction	Interventional procedures guidance
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer TS ID 10718	Technology appraisal guidance
Ensitrelvir for treating COVID 19 [ID6231]	Technology appraisal guidance
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more treatments [ID6338]	Technology appraisal guidance
Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037	Technology appraisal guidance
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]	Technology appraisal guidance
Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806	Technology appraisal guidance
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920	Technology appraisal guidance
Favezelimab–pembrolizumab for previously treated PD-L1-positive metastatic colorectal cancer [ID6278]	Technology appraisal guidance
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment TS ID 11963	Technology appraisal guidance
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]	Technology appraisal guidance
Galcanezumab for migraine TS ID 10663	Technology appraisal guidance
Gambling	Quality standard
Gantenerumab for treating early Alzheimer's disease TS ID 10668	Technology appraisal guidance
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over ID6394	Technology appraisal guidance
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]	Technology appraisal guidance
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A TS ID 9772	Technology appraisal guidance
Gosuranemab for treating progressive supranuclear palsy [ID1607]	Technology appraisal guidance
Gout	Quality standard
Heart valve disease in adults	Quality standard

Results per page

10
25
50
All